Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVLA vs Fondaparinux for Acute GSV Thrombophlebitis
NCT05001776Phase 4Completed
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (3 arms), sponsored by National Medical Research Center for Therapy and Preventive Medicine. Primary endpoints: Composite of deep vein thrombosis, symptomatic pulmonary embolism, superficial vein thrombosis extension, superficial vein thrombosis recurrence or thrombosis of subfascial part of perforating veins at 45 days and Major bleedings at 45 days. Started Aug 2021; status: completed.
Beyond the preview
Go deeper on NCT05001776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001776.